Drug Search Results
More Filters [+]

IMX-111

Alternative Names: IMX-111, IMX111
Latest Update: 2021-12-20
Latest Update Note: News Article

Product Description

IMX-111 is a preclinical drug candidate from Immix Biopharma for the treatment of colorectal cancer. (Sourced from: https://www.immixbio.com/pipeline/)

Mechanisms of Action: GLUT1 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Immix Biopharma
Company Location: LOS ANGELES CA 90064
Company CEO: Ilya Rachman
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IMX-111

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events